FASgen Announces New Discovery For Treatment Of Stroke

FASgen is pleased to announce the recent publication of important results from research into a potential treatment for stroke using one of FASgen’s proprietary compounds, C75. The Company is a leader in the research in the field of FASi (fatty acid synthase inhibition). One area of that research has been for the treatment of metabolic disease disorders, including obesity. [click link for full article]

More: continued here

Filed under: Stroke on December 23rd, 2007